Davis K L, Hollister L E, Overall J, Johnson A, Train K
Psychopharmacology (Berl). 1976 Dec 21;51(1):23-7. doi: 10.1007/BF00426316.
Physostigmine was given intravenously to a total dose of 3 mg to 13 subjects; a placebo of 0.25 N saline was given intravenously to 10 other subjects; both groups received 1 mg of methscopolamine bromide subcutaneously preceding the intravenous infusions. A "physostigmine syndrome" consisting of decreased speech, slowed thoughts, mild sedation, expressionless faces, nausea, and decreased spontaneous activity was evident following doses of 1.5 to 2.0 mg of physostigmine. The capacity of short-term memory (STM) as measured by digit span tasks was significantly less for the subjects who received physostigmine than for the subjects who received placebo. No difference was observed between the two groups on tasks of consolidation from STM to long-term memory (LTM). Subjects who received physostigmine did not significantly differ from subjects who received placebo in their mood. However, two subjects in the physostigmine group, and no subjects in the saline group became tearful and depressed.
对13名受试者静脉注射毒扁豆碱，总剂量为3毫克；对另外10名受试者静脉注射0.25N生理盐水作为安慰剂；两组在静脉输注前均皮下注射1毫克溴甲东莨菪碱。在注射1.5至2.0毫克毒扁豆碱后，出现了“毒扁豆碱综合征”，表现为言语减少、思维迟缓、轻度镇静、表情淡漠、恶心以及自发活动减少。通过数字广度任务测量的短期记忆（STM）能力，接受毒扁豆碱的受试者明显低于接受安慰剂的受试者。在从STM巩固到长期记忆（LTM）的任务上，两组之间未观察到差异。接受毒扁豆碱的受试者与接受安慰剂的受试者在情绪上没有显著差异。然而，毒扁豆碱组有两名受试者变得流泪和抑郁，而生理盐水组没有受试者出现这种情况。
